Crystalline p38α MAPK Inhibitor for Isoform-Selective Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing p38 MAPK inhibitors are poorly effective and cause toxicity due to non-specific inhibition of p38 isoforms, leading to a need for selective p38α MAPK inhibitors that preserve critical counterregulatory functions.
Innovation Solution
Development of crystalline 4-chloro-N-(4-(morpholinomethyl)phenyl)benzamide hydrochloride, which selectively inhibits p38α MAPK by targeting the substrate binding groove, thereby modulating p38α MAPK activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If p38 MAPK inhibitors are developed to treat inflammatory diseases, then therapeutic efficacy is improved, but toxicity increases due to non-specific inhibition of p38 isoforms
Solution Approach 1:
The patent applies segmentation by developing inhibitors that specifically target p38α MAPK isoform rather than inhibiting all p38 isoforms (α, β, γ, δ). This selective inhibition segments the therapeutic effect to only the desired isoform, achieving anti-inflammatory efficacy while avoiding toxicity from non-specific inhibition of other isoforms that perform critical counterregulatory functions
Solution Approach 2:
The patent employs local quality by designing compounds with specific molecular structures (such as 4-chloro-N-(4-(morpholinomethyl)phenyl)benzamide) that exhibit preferential binding affinity to p38α MAPK. This localized specificity ensures that the inhibitory effect is concentrated on the target isoform, maintaining therapeutic benefits while minimizing harmful effects on other isoforms
2Reliability
If broad-spectrum p38 MAPK inhibition is achieved, then anti-inflammatory effect is enhanced, but loss of counterregulatory responses occurs
Solution Approach 1:
The patent segments the inhibition effect to target only p38α MAPK isoform while sparing other isoforms (β, γ, δ) that are responsible for counterregulatory responses. This selective approach maintains the anti-inflammatory effect through p38α inhibition while preserving the homeostatic functions mediated by other isoforms
Solution Approach 2:
The patent applies partial action by implementing incomplete inhibition - specifically inhibiting only a portion of the p38 family (p38α) rather than all isoforms. This partial inhibition is sufficient to achieve anti-inflammatory effects while leaving enough p38 activity through other isoforms to maintain critical counterregulatory responses and prevent loss of homeostasis
Data Source
AI summary
Crystalline 4-chloro-N-(4-(morpholinomethyl)phenyl)benzamide, crystalline 4-chloro-N-(4-(morpholinomethyl)phenyl)benzamide hydrochloride, methods of preparing the crystalline compounds, pharmaceutical compositions containing the crystalline compounds, and methods of treatment using the crystalline compounds are disclosed.